



C Britschgi

Kontakt

C Britschgi

Publikationen (3)

Schmid S, Jochum W, Padberg B, Demmer I, Mertz K, Joerger M, Britschgi C, Matter M, Rothschild S, Omlin A. How to read a next-generation sequencing report-what oncologists need to know. *ESMO Open* 2022; 7:100570.

Soo R, Han J, Dafni U, Cho B, Yeo C, Nadal E, Carcereny E, de Castro J, Sala M, Bernabé R, Coate L, Provencio Pulla M, Garcia Campelo R, Cuffe S, Hashemi S, Früh M, Massuti B, Garcia-Sanchez J, Dómine M, Majem M, Sanchez-Torres J, Britschgi C, Pless M, Dimopoulou G, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel R, Peters S, ETOP 10-16 BOOSTER Collaborators. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial. *Ann Oncol* 2021; 33:181-192.

Schmid S, Jochum W, Demmer I, Foerbs D, Janthur W, Wannesson L, Rothschild S, Pless M, Gautschi O, Britschgi C, Aeppli S, Klingbiel D, Früh M. Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study. *Lung Cancer* 2019; 130:149-155.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch